Focus on launch metrics (prescriptions, patient starts) and payer coverage for the new indication. The existing commercial presence for MDD may accelerate uptake. Monitor competitor activity in Alzheimer's agitation (e.g., brexpiprazole). Revenue guidance updates in upcoming earnings will be key.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $207.75entry
- T+1 · 7mo ago −0.59%α −0.81% · $206.53
- T+5 · 6mo ago +7.16%α +5.43% · $222.63
- T+20 · 6mo ago +12.07%α +7.10% · $232.83
- T+60 · 4mo ago +14.74%α +11.63% · $238.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agitation associated with dementia due to Alzheimer's disease, a second indication for the drug. The approval, granted under Priority Review with Breakthrough Therapy designation, addresses a large unmet need affecting up to 76% of the 7+ million Alzheimer's patients in the U.S. This label expansion significantly expands AUVELITY's commercial opportunity beyond its existing major depressive disorder indication.
Key Facts
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026
- Approval based on Phase 3 ADVANCE-1 and ACCORD-2 studies showing statistically significant improvement in agitation symptoms and longer time to relapse
- Alzheimer's disease affects >7 million Americans; agitation reported in up to 76% of patients
- AUVELITY already approved for major depressive disorder (2022) with >300,000 patients exposed and commercial infrastructure in place
- Patent protection extends to at least 2043
Financial Impact
Approval opens a large new market: up to ~5.3 million Alzheimer's patients with agitation. AUVELITY's existing MDD revenue was $X (not disclosed); this indication could materially accelerate revenue growth.
Risk Factors
- Boxed warning for suicidal thoughts and behaviors may limit use in elderly patients
- Competition from other treatments for Alzheimer's agitation (e.g., brexpiprazole) and off-label antipsychotics
- Reimbursement and pricing dynamics could slow adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285345 |
Track record
26 reports on AXSM
5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +13.40% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers